» Articles » PMID: 34583923

Novel Aspects of Regulatory T Cell Dysfunction As a Therapeutic Target in Giant Cell Arteritis

Abstract

Objectives: Giant cell arteritis (GCA) is the most common primary vasculitis, preferentially affecting the aorta and its large-calibre branches. An imbalance between proinflammatory CD4 T helper cell subsets and regulatory T cells (Tregs) is thought to be involved in the pathogenesis of GCA and Treg dysfunction has been associated with active disease. Our work aims to explore the aetiology of Treg dysfunction and the way it is affected by remission-inducing immunomodulatory regimens.

Methods: A total of 41 GCA patients were classified into active disease (n=14) and disease in remission (n=27). GCA patients' and healthy blood donors' (HD) Tregs were sorted and subjected to transcriptome and phenotypic analysis.

Results: Transcriptome analysis revealed 27 genes, which were differentially regulated between GCA-derived and HD-derived Tregs. Among those, we identified transcription factors, glycolytic enzymes and IL-2 signalling mediators. We confirmed the downregulation of forkhead box P3 (FOXP3) and interferon regulatory factor 4 (IRF4) at protein level and identified the ineffective induction of glycoprotein A repetitions predominant (GARP) and CD25 as well as the reduced T cell receptor (TCR)-induced calcium influx as correlates of Treg dysfunction in GCA. Inhibition of glycolysis in HD-derived Tregs recapitulated most identified dysfunctions of GCA Tregs, suggesting the central pathogenic role of the downregulation of the glycolytic enzymes. Separate analysis of the subgroup of tocilizumab-treated patients identified the recovery of the TCR-induced calcium influx and the Treg suppressive function to associate with disease remission.

Conclusions: Our findings suggest that low glycolysis and calcium signalling account for Treg dysfunction and inflammation in GCA.

Citing Articles

The IL-17 pathway as a target in giant cell arteritis.

Zeisbrich M, Thiel J, Venhoff N Front Immunol. 2024; 14:1199059.

PMID: 38299156 PMC: 10828953. DOI: 10.3389/fimmu.2023.1199059.


Metabolic regulation of forkhead box P3 alternative splicing isoforms and their impact on health and disease.

Luo Z, Zhang Y, Saleh Q, Zhang J, Zhu Z, Tepel M Front Immunol. 2023; 14:1278560.

PMID: 37868998 PMC: 10588449. DOI: 10.3389/fimmu.2023.1278560.


Changes in the molecular profiles of large-vessel vasculitis treated with biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors.

Matsumoto K, Suzuki K, Takeshita M, Takeuchi T, Kaneko Y Front Immunol. 2023; 14:1197342.

PMID: 37197652 PMC: 10183585. DOI: 10.3389/fimmu.2023.1197342.


CD8 Regulatory T Cell Deficiency in Elderly-Onset Rheumatoid Arthritis.

Watanabe R, Kadoba K, Tamamoto A, Murata K, Murakami K, Onizawa H J Clin Med. 2023; 12(6).

PMID: 36983342 PMC: 10054757. DOI: 10.3390/jcm12062342.


Distinct gene signatures of monocytes and B cells in patients with giant cell arteritis: a longitudinal transcriptome analysis.

Matsumoto K, Suzuki K, Yoshida H, Magi M, Matsumoto Y, Noguchi-Sasaki M Arthritis Res Ther. 2023; 25(1):1.

PMID: 36597161 PMC: 9809009. DOI: 10.1186/s13075-022-02982-9.


References
1.
Sogkas G, Atschekzei F, Adriawan I, Dubrowinskaja N, Witte T, Schmidt R . Cellular and molecular mechanisms breaking immune tolerance in inborn errors of immunity. Cell Mol Immunol. 2021; 18(5):1122-1140. PMC: 8015752. DOI: 10.1038/s41423-020-00626-z. View

2.
Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A . Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006; 203(7):1693-700. PMC: 2118333. DOI: 10.1084/jem.20060468. View

3.
Ichiyama K, Yoshida H, Wakabayashi Y, Chinen T, Saeki K, Nakaya M . Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J Biol Chem. 2008; 283(25):17003-8. DOI: 10.1074/jbc.M801286200. View

4.
Stone J, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D . Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017; 377(4):317-328. DOI: 10.1056/NEJMoa1613849. View

5.
Mailer R . Alternative Splicing of FOXP3-Virtue and Vice. Front Immunol. 2018; 9:530. PMC: 5859138. DOI: 10.3389/fimmu.2018.00530. View